Mean eDiary-assessed peak expiratory flow (L·min−1) during dosing periods (averaged across all 4-weekly dosing periods within the DREAM study)
| Dosing period | Placebo (n=155) | Mepolizumab | ||
| 75 mg (n=153) | 250 mg (n=152) | 750 mg (n=156) | ||
| First 2 weeks (days 1–14) | ||||
| n# | 152 | 151 | 151 | 154 |
| Mean (sd) | 276.2 (106.3) | 278.1 (111.5) | 288.4 (125.8) | 283.2 (119.8) |
| Second 2 weeks (days 15–28) | ||||
| n# | 152 | 151 | 151 | 154 |
| Mean (sd) | 276.6 (108.1) | 277.6 (111.3) | 286.3 (126.4) | 283.1 (120.2) |
| Mean change (sd) | 0.4 (15.2) | −0.5 (7.8) | −2.1 (7.5) | −0.2 (7.5) |
| ≥0 L·min−1 decrease | 87 (57%) | 83 (55%) | 99 (66%) | 79 (51%) |
| ≥10 L·min−1 decrease | 14 (9%) | 14 (9%) | 16 (11%) | 9 (6%) |
| ≥20 L·min−1 decrease | 1 (<1%) | 0 | 3 (2%) | 2 (1%) |
#: Patients with ≥7 days eDiary data for both 2-week periods of at least one dosing interval were included in the analysis.